Journal
BIOMEDICINE-TAIWAN
Volume 4, Issue 2, Pages 51-53Publisher
DIGITAL COMMONS BEPRESS
DOI: 10.7603/s40681-014-0015-0
Keywords
Carbamazepine; Paroxysmal dyskinesia; PRRT2; Mutation
Categories
Funding
- China Medical University Hospital [DMR-103-034]
Ask authors/readers for more resources
Paroxysmal kinesigenic dyskinesia (PKD), a rare paroxysmal movement disorder often misdiagnosed as epilepsy, is characterized by recurrent, brief dyskinesia attacks triggered by sudden voluntary movement. Pathophysiological mechanism of PKD remains not well understood. Ion channelopathy has been suggested, since the disease responds well to ion channel blockers. Mutations in proline-rich transmembrane protein 2 (PRRT2) were recently identified in patients with familial PKD. To extend these genetic reports, we studied a family with clinical manifestations of familial PKD responding well to low dose carbamazepine. Therapeutic dose ranged from 1.5 to 2.0 mg/kg/day, below that in seizure control. One insertion mutation c. 649_650insC (p.P217fsX7) was identified in three patients of the family. This study avers PRRT2's high sensitivity for PKD phenotype. Identification of genes underlying pathogenesis will enhance diagnosis and treatment. Function of PRRT2 and its role in PKD warrant further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available